Detecting minimal residual disease in neuroblastoma: The superiority of a panel of real-time quantitative PCR markers

Clinical Chemistry

Volumn 55, Issue 7, 2009, Pages 1316-1326

  Stutterheim, Janine ^a,b   Gerritsen, Annemieke ^b   Zappeij Kannegieter, Lily ^b   Yalcin, Bilgehan ^c   Dee, Rob ^b   Van Noesel, Max M ^d   Berthold, Frank ^e   Versteeg, Rogier ^b   Caron, Huib N ^a   Van Der Schoot, C Ellen ^a,b,f   Tytgat, Godelieve A M ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c HACETTEPE UNIVERSITY   (Turkey)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^e UNIVERSITY OF COLOGNE   (Germany)

^f NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DISIALOGANGLIOSIDE ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; BONE MARROW; BONE MARROW METASTASIS; BONE METASTASIS; CANCER STAGING; CELL POPULATION; CHRNA3 GENE; CONTROLLED STUDY; CYTOLOGY; DBH GENE; DDC GENE; GAP43 GENE; GENE; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MONITORING; NEUROBLASTOMA; PHOX2B GENE; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SERIAL ANALYSIS OF GENE EXPRESSION; SOLID TUMOR; TH GENE; TREATMENT RESPONSE; TUMOR;

HUMANS; NEOPLASM, RESIDUAL; NEUROBLASTOMA; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 67650077150     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2008.117945     Document Type: Article

References (40)

1. Cotterill SJ, Pearson AD, Pritchard J, Foot AB, Roald B, Kohler JA, Imeson J. Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992. Eur J Cancer 2000;36:901-8.
2. Hartmann O, Valteau-Couanet D, Vassal G, Lapierre V, Brugieres L, Delgado R, et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 1999;23:789-95.
3. Fukuda M, Miyajima Y, Miyashita Y, Horibe K. Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study. J Pediatr Hematol Oncol 2001;23:10-3.
4. Seeger RC, Reynolds CP, Gallego R, Stram DO, Gerbing RB, Matthay KK. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2000;18:4067-76.
5. Burchill SA, Kinsey SE, Picton S, Roberts P, Pinkerton CR, Selby P, Lewis IJ. Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. Med Pediatr Oncol 2001;36:213-9.
6. Corrias MV, Haupt R, Carlini B, Parodi S, Rivabella L, Garaventa A, et al. Peripheral blood stem cell tumor cell contamination and survival of neuroblastoma patients. Clin Cancer Res 2006;12:5680-5.
7. Cheung NK, Heller G, Kushner BH, Liu C, Cheung IY. Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive? J Clin Oncol 1997;15:2807-17.
8. Mehes G, Luegmayr A, Kornmuller R, Ambros IM, Ladenstein R, Gadner H, Ambros PF. Detection of disseminated tumor cells in neuroblastoma: 3 log improvement in sensitivity by automatic immunofluorescence plus FISH (AIPF) analysis compared with classical bone marrow cytology. Am J Pathol 2003;163:393-9.
9. Viprey VF, Corrias MV, Kagedal B, Oltra S, Swerts K, Vicha A, et al. Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: quality assurance on behalf of SIOPEN-R-NET. Eur J Cancer 2007;43:341-50.
10. Mehes G, Luegmayr A, Ambros IM, Ladenstein R, Ambros PF. Combined automatic immunological and molecular cytogenetic analysis allows exact identification and quantification of tumor cells in the bone marrow. Clin Cancer Res 2001;7:1969-75.
11. Swerts K, Ambros PF, Brouzes C, Navarro JM, Gross N, Rampling D, et al. Standardization of the immunocytochemical detection of neuroblastoma cells in bone marrow. J Histochem Cytochem 2005;53:1433-40.
12. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, Dee R, Hooft L, et al. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. J Clin Oncol 2008;26:5443-9.
13. Cheung IY, Cheung NK. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. Clin Cancer Res 2001;7:1698-705.
14. Kuci Z, Seitz G, Kuci S, Kreyenberg H, Schumm M, Lang P, et al. Pitfalls in detection of contaminating neuroblastoma cells by tyrosine hydroxylase RT-PCR due to catecholamine-producing hematopoietic cells. Anticancer Res 2006;26:2075-80.
15. Verhagen OJ, Willemse MJ, Breunis WB, Wijkhuijs AJ, Jacobs DC, Joosten SA, et al. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 2000;14:1426-35.
16. Weening RS, Roos D, Loos JA. Oxygen consumption of phagocytizing cells in human leukocyte and granulocyte preparations: a comparative study. J Lab Clin Med 1974;83:570-7.
17. Tijssen MR, van Hennik PB, di Summa F, Zwaginga JJ, van der Schoot CE, Voermans C. Transplantation of human peripheral blood CD34-positive cells in combination with ex vivo generated megakaryocytes results in fast platelet formation in NOD/SCID mice. Leukemia 2008;22:203-8.
18. Kerst JM, van de Winkel JG, Evans AH, de Haas M, Slaper-Cortenbach IC, de Wit TP, et al. Granulocyte colony-stimulating factor induces hFc gamma RI (CD64 antigen)-positive neutrophils via an effect on myeloid precursor cells. Blood 1993;81:1457-64.
19. + cells in NOD/SCID mice. Exp Hematol 2003;31:881-9.
20. Rood PM, Calafat J, dem Borne AE, Gerritsen WR, van der Schoot CE. Immortalisation of human bone marrow endothelial cells: characterisation of new cell lines. Eur J Clin Invest 2000;30:618-29.
21. Varma MJ, Breuls RG, Schouten TE, Jurgens WJ, Bontkes HJ, Schuurhuis GJ, et al. Phenotypical and functional characterization of freshly isolated adipose tissue-derived stem cells. Stem Cells Dev 2007;16:91-104.
22. Pires NM, Pols TW, de Vries MR, van Tiel CM, Bonta PI, Vos M, et al. Activation of nuclear receptor Nur77 by 6-mercaptopurine protects against neointima formation. Circulation 2007;115:493-500.
23. Van Kuilenburg AB, Van Lenthe H, Tromp A, Veltman PC, Van Gennip AH. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem 2000;46:9-17.
24. Caron H, van Schaik B, van der Mee M, Baas F, Riggins G, van Sluis P, et al. The human transcriptome map: clustering of highly expressed genes in chromosomal domains. Science 2001;291:1289-92.
25. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003;17:2474-86.
26. Swerts K, De Moerloose B, Dhooge C, Vandesompele J, Hoyoux C, Beiske K, et al. Potential application of ELAVL4 real-time quantitative reverse transcription-PCR for detection of disseminated neuroblastoma cells. Clin Chem 2006;52:438-45.
27. Collantes-Fernandez E, Zaballos A, Alvarez-Garcia G, Ortega-Mora LM. Quantitative detection of Neospora caninum in bovine aborted fetuses and experimentally infected mice by realtime PCR. J Clin Microbiol 2002;40:1194-8.
28. van der Velden V, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007;21:604-11.
29. Burchill SA, Bradbury FM, Selby P, Lewis IJ. Early clinical evaluation of neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. Eur J Cancer 1995;31A:553-6.
30. Trager C, Kogner P, Lindskog M, Ponthan F, Kullman A, Kagedal B. Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow. Clin Chem 2003;49:104-12.
31. Bozzi F, Luksch R, Collini P, Gambirasio F, Barzano E, Polastri D, et al. Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma. Diagn Mol Pathol 2004;13:135-43.
32. Cheung IY, Lo Piccolo MS, Kushner BH, Kramer K, Cheung NK. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol 2003;21:1087-93.
33. Cheung IY, Cheung NK. Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma. Clin Cancer Res 1997;3:821-6.
34. Wang Y, Einhorn P, Triche TJ, Seeger RC, Reynolds CP. Expression of protein gene product 9.5 and tyrosine hydroxylase in childhood small round cell tumors. Clin Cancer Res 2000;6:551-8.
35. Lai PS, Chee S, Chiu LL, Sano K. Detection of low numbers of neuroblastoma cells in vitro. Ann Acad Med Singapore 1997;26:415-20.
36. Sasaki H, Sato Y, Kondo S, Fukai I, Kiriyama M, Yamakawa Y, Fuji Y. Expression of the periostin mRNA level in neuroblastoma. J Pediatr Surg 2002;37:1293-7.
37. Cheung IY, Feng Y, Gerald W, Cheung NK. Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma. Clin Cancer Res 2008;14:7020-7.
38. Viprey VF, Lastowska MA, Corrias MV, Swerts K, Jackson MS, Burchill SA. Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials. J Pathol 2008;216:245-52.
39. Handgretinger R, Leung W, Ihm K, Lang P, Klingebiel T, Niethammer D. Tumour cell contamination of autologous stem cells grafts in high-risk neuroblastoma: the good news? Br J Cancer 2003;88:1874-7.
40. Tchirkov A, Kanold J, Giollant M, Halle-Haus P, Berger M, Rapatel C, et al. Molecular monitoring of tumor cell contamination in leukapheresis products from stage IV neuroblastoma patients before and after positive CD34 selection. Med Pediatr Oncol 1998;30:228-32.